The author of this article wanted to change the ethical approval statement of the originally published version of this article. Correct statement is indicated below.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828288 | PMC |
| http://dx.doi.org/10.1007/s00259-019-04401-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficient Production of the PET Radionuclide La for Theranostic Purposes in Targeted Alpha Therapy Using the Ba(p,2n)La Reaction.
Pharmaceuticals (Basel)
September 2022
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D-01328 Dresden, Germany.
Targeted Alpha Therapy is a research field of highest interest in specialized radionuclide therapy. Over the last decades, several alpha-emitting radionuclides have entered and left research topics towards their clinical translation. Especially, 225Ac provides all necessary physical and chemical properties for a successful clinical application, which has already been shown by [225Ac]Ac-PSMA-617.
View Article and Find Full Text PDFCorrection to: Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
Eur J Nucl Med Mol Imaging
September 2019
Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Private Bag X169, Pretoria, 0001, South Africa.
The author of this article wanted to change the ethical approval statement of the originally published version of this article. Correct statement is indicated below.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!